• Agora
  • Eioc Mededge
  • Holistic Health 2025 MedEdge
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: WHO Urges Quick Access to Mpox Tests
Share
Notification
  • Agora
  • Eioc Mededge
  • Holistic Health 2025 MedEdge
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > News > WHO Urges Quick Access to Mpox Tests
News

WHO Urges Quick Access to Mpox Tests

ME Desk
ME Desk
Published: August 31, 2024
Share
4 Min Read
WHO Urges Quick Access to Mpox Tests
SHARE

WHO has asked manufacturers of mpox in vitro diagnostics (IVDs) to submit an expression of interest for Emergency Use Listing (EUL). World health organization (WHO) has been in ongoing discussions with manufacturers about the need for effective diagnostics, particularly in low-income settings. The request for EUL expressions of interest by manufacturers is the latest development in these discussions.

Testing is key for people to get treatment and care as early as possible and prevent further spread. Since 2022, WHO has delivered around 150 000 diagnostic tests for Monkey Pox globally, of which over a quarter have gone to countries in the African Region. In the coming weeks, WHO will deliver another 30 000 tests to African countries.

With as many as 1000 suspected cases reported in the Democratic Republic of the Congo alone this week, the demand for diagnostic tests is on the rise. In this heavily affected country, WHO has worked with partners to scale up diagnostic capacity to respond to the upsurge of cases. Since May 2024, six additional labs have equipped themselves to diagnose mpox, decentralizing testing capacity from major cities to affected provinces. Two of these labs are in South Kivu, selected to respond to the outbreak of the new viral strain, called Ib. Thanks to these efforts, testing rates have dramatically improved in the country, with four times as many samples tested in 2024 so far as compared to 2023.

WHO has also updated its diagnostic testing guidance to detect the new virus strain and is working with countries to roll it out. Earlier, WHO issued target product profiles to guide manufacturers in the development of new diagnostic tests.

WHO Director-General Dr Tedros Adhanom Ghebreyesus declared on 14 August 2024 that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005).

Also Read: WHO declares Global Emergency over mpox outbreak. Here’s all you need to know.

Manufacturers of IVDs are now asked to submit available quality, safety and performance data to WHO as soon as they can. IVDs are tests done in laboratories to detect a pathogen. Detection of viral DNA by PCR (Polymerase Chain Reaction) testing is the gold standard for mpox diagnosis. It detects the virus’s DNA in samples taken from skin lesions, such as fluid or crusts from vesicles or pustules. Routine diagnosis does not recommend blood testing, and retrospective case classification should use antibody detection methods but not for diagnosis.

Through the EUL procedure, WHO can approve medical products such as vaccines, tests and treatments for use, evaluating the acceptability of using specific products for time-limited procurement in emergency situations. The process aims to assist countries, which have not approved the medical products through national approval processes, to procure the critically needed products such as tests through UN agencies and other partners.

Expanding access to diagnostic services urgently addresses the need for tests that strengthen laboratory capacity, improve case investigation, enhance contact tracing, collect surveillance data, and ensure timely reporting. As a package, these help countries identify chains of transmission, detect cases early, prevent further spread, and monitor the virus in real-time. The establishment of Emergency Use Listing procedures for mpox diagnostic tests will help advance towards this goal.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article Lancet Study: Semaglutide Reduces Risk of CV Death and Worsening Heart Failure Lancet Study: Semaglutide Reduces Risk of CV Death and Worsening Heart Failure
Next Article BinSina Pharmacy invites UAE to celebrate 59 years of well-being BinSina Pharmacy invites the UAE to celebrate 59 years of well-being together

Recent Posts

  • Samsung Galaxy Watch8 Series: Ultra Comfort, from Sleep to Workout
  • Emirates Health Services Participates in Drug Prevention Forum 2025
  • Abu Dhabi Concludes Fourth Consecutive U.S. Mission Further Reinforcing Global Healthcare Leadership
  • WHO welcomes IMF support to Jordan for pandemic preparedness and response
  • Achieving Smart Safety Monitoring: Navigating Risks in Today’s Complex Trials
  • LifeSpin
  • Health ExpoIraq
  • Agora
  • Holistic Health Middle East
  • Holistic Health Middle East MedEdge
  • GHE square advert MedEdge
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: WHO Urges Quick Access to Mpox Tests
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: WHO Urges Quick Access to Mpox Tests
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp

WhatsApp us

Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?